Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

This research study is for people who have relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL) that has not responded to two or more lines of therapy. The purpose of this study is to identify the recommended dose of allogeneic NK cells in combination with IL-2, Tafasitamab and Rituximab for the treatment of relapsed or refractory B-cell non-Hodgkin's lymphoma. NK cells are an investigational (experimental) treatment which means they are not approved by the Food and Drug Administration (FDA). NK cells are a type of lymphocyte that's part of the body's natural immune system, and they can

Trial Details

NCT ID
NCT07225439
Phase
PHASE1
Sponsor
Paolo Caimi, MD
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Allogeneic NK cells
  • Rituximab
  • Tafasitamab
  • Interleukin-2
  • Fludarabine/cyclophosphamide
Locations (sample)
  • Cleveland, Ohio, United States|41.4995,-81.69541
  • Cleveland, Ohio, United States|41.4995,-81.69541

Key Eligibility Criteria

  • Age 18 years or older
  • Diagnosis of B-cell NHL (indolent and aggressive subtypes) including diffuse large B-cell lymphoma not otherwise specified (DLBCL NOS), high grade …
  • Participants must have measurable disease as defined by Lugano 2014 criteria for NHL or iwCLL 2018 criteria for CLL. For NHL, measurable disease is…
  • Relapsed and/or refractory after two or more lines of systemic therapy, including prior CD19 and/or CD20 directed therapies

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →